Quest PharmaTech Announces Clinical Development Agreement with Hemispherx Biopharma Inc. to evaluate a combinatorial Immunotherapy Technology

April 14, 2011

TSX Venture: QPT

EDMONTON, April 14 /PRNewswire-FirstCall/ – Quest PharmaTech Inc. (TSX-V: QPT) (“Quest”
or the “Company”), a pharmaceutical company developing and
commercializing products for the treatment of cancer, today announced a
clinical development arrangement with U.S. based Hemispherx Biopharma
Inc. to evaluate the clinical utility of combining Quest’s antibody
immunotherapy technology with Hemispherx’s immune activator in a thirty
patient clinical trial.

Under the terms of the agreement the costs of the clinical trial will be
shared equally by Quest and Hemispherx. In addition, Hemispherx will
provide appropriate technical expertise and relevant data to support
the regulatory process necessary to conduct the clinical trial.
Hemispherx has also agreed to store and maintain clinical supply
inventory of Oregovomab at their state of the art manufacturing
facility in New Brunswick.

“This collaborative clinical study is indicative of our progression as a
cancer immunotherapy company and we look forward to working with
Hemispherx in the conduct of this important clinical trial to evaluate
the utility of our product in combination with Ampligen”, said Dr. Madi
R. Madiyalakan, Quest’s Chief Executive Officer. The Company is in
negotiation with various investigators in Canada and the U.S. to
initiate this clinical study in the coming months.

About Hemispherx Biopharma Inc.

Based in Philadelphia, Hemispherx Biopharma is a biopharmaceutical
company engaged in clinical development, manufacture and sale of new
drugs for the treatment of viral diseases and serious debilitating
disorders. Its flagship products include Alferon N Injection, Alferon
LDO and the experimental therapeutics Ampligen and Oragens.

Ampligen is a double -stranded RNA immune activating therapeutic that
interacts uniquely with TLR 3 pathway and is biologically active in
multiple clinical conditions. Ampligen is currently in clinical
development most notably for Chronic Fatigue Syndrome, but also, West
Nile Virus and SARS. A new cancer initiative is also being undertaken
by Hemispherx. Recent preclinical studies published by Quest’s clinical
advisor Dr. Christopher Nicodemus, MD, FACP indicated that Ampligen
could potentially be used as a vaccine enhancer for cancer
immunotherapy including with Quest’s antibody technology.

About Quest PharmaTech Inc.

Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment of
cancer based on its pipeline of SonoLight compounds and monoclonal
antibodies which target certain tumor antigens that are presented in a
variety of cancers. Quest believes that by combining these antibodies
with other cancer therapies such as chemotherapy, photodynamic therapy
or radioimmuno-therapy, it can potentially further complement and
enhance treatment outcomes compared to antibody treatment alone.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

SOURCE Quest PharmaTech Inc.

Source: newswire

comments powered by Disqus